The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Indications/Uses
ORSERDU monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign Out
